Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 31 Buyback Yield % is 0.00 as of Jul. 24, 2026. GuruFocus rates BIOE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 290 Drug Manufacturers companies, Bio Essence ranks worse than 344827.24% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Bio Essence's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOE vs BFRI, APUS, CABR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Bio Essence's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence (BIOE) has a Buyback Yield % of 0.00 as of Jul. 24, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bio Essence and its competitors. According to the industry distribution chart, Bio Essence ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Bio Essence's Buyback Yield % too high?
Bio Essence's current Buyback Yield % is 0.00. Based on the distribution chart, Bio Essence ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bio Essence has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's Buyback Yield % compare to BFRI and APUS?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #999999 out of 290 companies for Buyback Yield %. This places Bio Essence in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bio Essence and its competitors. Bio Essence's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Bio Essence's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Bio Essence (BIOE), the current Buyback Yield % is 0.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
31GF Score
Get the complete analysis for BIOE
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
